1. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy
- Author
-
Isla Leslie, James Larkin, Lisa Pickering, and Laura Amanda Boos
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Axitinib ,medicine.drug_class ,medicine.medical_treatment ,Antibodies, Monoclonal, Humanized ,urologic and male genital diseases ,Tyrosine-kinase inhibitor ,Avelumab ,03 medical and health sciences ,0302 clinical medicine ,Combined treatment ,Renal cell carcinoma ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Pharmacology (medical) ,Carcinoma, Renal Cell ,business.industry ,Incidence (epidemiology) ,Immunotherapy ,medicine.disease ,Kidney Neoplasms ,Progression-Free Survival ,Survival Rate ,Treatment Outcome ,030104 developmental biology ,030220 oncology & carcinogenesis ,Disease Progression ,bacteria ,business ,Renal carcinoma ,medicine.drug - Abstract
Introduction: The incidence of advanced renal cell carcinoma (RCC) is increasing. Over the last 10 years targeted therapies have led to improved efficacy outcomes for renal carcinoma, including lon...
- Published
- 2020
- Full Text
- View/download PDF